Molecular Diagnostics at the Point of Care Market Research 2025-2029: New Genotypes Creating New Markets, Aging Population a Boon for All Diagnostics, Developing World Driving ID Dx Growth - ResearchAndMarkets.com

The "Molecular Diagnostics at the Point of Care 2025-2029: By Application, Technology, Place, Product and Country, with Executive Guides and Analysis" has been added to ResearchAndMarkets.com's offering.

Molecular Diagnostics at the Point of Care is on the brink of unprecedented growth, offering transformative changes in healthcare outcomes and cost-efficiency. This burgeoning market segment is being propelled by advancements in technology and increasing demand for rapid, reliable testing solutions available right at the patient's bedside.

Recent data indicates an impressive upward trajectory in market performance, driven in part by major players who are consistently reporting robust growth figures. One of the key catalysts for this surge is the technology's capability to significantly reduce costs while simultaneously enhancing diagnostic outcomes. Importantly, it plays a vital role in combating Anti-Microbial Resistance, presenting a compelling case for its wider adoption.

With a market poised to potentially disrupt traditional testing protocols, stakeholders are keen on understanding both the challenges and future outlooks this development entails. This comprehensive report offers an in-depth forecast of the market size over the next five years, enabling stakeholders to align strategies and optimize operations effectively.

Equipped with this knowledge, industry experts can gain a competitive edge, leveraging this detailed analysis to inform decision-making processes. Complementing the report, additional specific data and expert assistance are readily available, ensuring that professionals have access to precise and actionable insights without incurring extra charges.

For a deeper dive, all report data can be accessed in Excel format upon request, providing a versatile tool for robust investment decisions and accurate valuations. This flexibility ensures that financial assessments and strategic planning are grounded in the most up-to-date information.

As the Molecular Diagnostics at Point of Care market continues to evolve, staying informed and prepared is more critical than ever. This report serves as an essential resource for organizations looking to harness these market developments and drive forward-thinking strategies in the healthcare domain.

Key Topics Covered:

1 Market Guides

1.1 Strategic Situation Analysis

1.2 Guide for Executives, Marketing and Business Development Staff

1.3 Guide for Management Consultants and Investment Advisors

2 Introduction and Market Definition

2.1 What are Molecular Diagnostics at the Point of Care?

2.2 The Diagnostics Revolution

2.3 Market Definition

2.4 Methodology

2.5 Perspective: Healthcare Spending

3 Instrumentation, Automation and Diagnostic Trends

3.1 Instrumentation and Automation

3.1.1 Traditional Automation and Centralization

3.1.2 The New Automation, Decentralization and Point Of Care

3.1.3 Instruments Key to Market Share

3.1.4 Bioinformatics Plays a Role

3.1.5 PCR Takes Command

3.1.6 Next Generation Sequencing Fuels a Revolution

3.1.7 NGS Impact on Pricing

3.1.8 Whole Genome Sequencing, A Brave New World

3.1.9 Companion Diagnostics Blurs Diagnosis and Treatment

4 Industry Overview

4.1 Players in a Dynamic Market

4.1.1 Academic Research Lab

4.1.2 Diagnostic Test Developer

4.1.3 Instrumentation Supplier

4.1.4 Chemical/Reagent Supplier

4.1.5 Pathology Supplier

4.1.6 Independent Clinical Laboratory

4.1.7 Public National/regional Laboratory

4.1.8 Hospital Laboratory

4.1.9 Physicians Office Lab (POLS)

4.1.10 Audit Body

4.1.11 Certification Body

4.2 The Clinical Laboratory Market Segments

4.2.1 Traditional Market Segmentation

4.2.2 Laboratory Focus and Segmentation

4.3 Industry Structure

4.3.1 Hospital Testing Share

4.3.2 Economies of Scale

4.3.2.1 Hospital vs. Central Lab

4.3.3 Physician Office Lab's

4.3.4 Physician's and POCT

5 Profiles of Key MDx Companies

5.1 Abbott Laboratories

5.2 Abionic

5.3 Accelerate Diagnostics

5.4 Access Bio

5.5 Ador Diagnostics

5.6 ADT Biotech

5.7 Akonni Biosystems

5.8 Alveo Technologies

5.9 Anitoa

5.10 Applied BioCode

5.11 Aureum Diagnostics

5.12 Aus Diagnostics

5.13 Autonomous Medical Devices

5.14 Baebies

5.15 Beckman Coulter Diagnostics (Danaher)

5.16 Becton, Dickinson and Company

5.17 Binx Health

5.18 Biocartis

5.19 BioFire Diagnostics (bioMerieux)

5.20 bioMerieux Diagnostics

5.21 Bio-Rad Laboratories, Inc

5.22 Bosch Healthcare Solutions GmbH

5.23 Cepheid (Danaher)

5.24 Credo Diagnostics Biomedical

5.25 Cue Health

5.26 Curetis (OpGen)

5.27 Detect

5.28 Diagenode Diagnostics (Hologic)

5.29 Diasorin S.p.A.

5.30 DNAe

5.31 Domus Diagnostics

5.32 Enzo Biochem

5.33 Eurofins Scientific

5.34 Fluxergy

5.35 Fusion Genomics.

5.36 Genedrive

5.37 Genetic Signatures

5.38 GenMark Dx (Roche)

5.39 Genomadix

5.40 Getlabs

5.41 Global Access Diagnostics

5.42 Grip Molecular Technologies

5.43 Hologic

5.44 Immunexpress

5.45 Inflammatix

5.46 Invetech

5.47 Iollo

5.48 J&J Innovative Medicine

5.49 Karius

5.50 Lucira Health (Pfizer)

5.51 LumiraDx

5.52 Maxim Biomedical

5.53 Meep

5.54 Meridian Bioscience

5.55 Millipore Sigma

5.56 Molbio Diagnostics

5.57 NanoDx

5.58 Nanomix

5.59 Novacyt

5.60 Novel Microdevices

5.61 Novus Diagnostics

5.62 Nuclein

5.63 OnsiteGene

5.64 Operon

5.65 OraSure Technologies

5.66 Oxford Nanopore Technologies

5.67 Panagene

5.68 Prenetics

5.69 Primerdesign (Novacyt)

5.70 Prominex

5.71 Proof Diagnostics

5.72 Qiagen

5.73 QuantuMDx

5.74 QuidelOrtho

5.75 R-Biopharm AG

5.76 Response Biomedical

5.77 Revvity

5.78 Roche Diagnostics

5.79 Salignostics

5.80 SD Biosensor

5.81 Seegene

5.82 Sekisui Diagnostics

5.83 Siemens Healthineers

5.84 Sona Nanotech

5.85 SpeeDx

5.86 T2 Biosystems

5.87 Talis Biomedical

5.88 Thermo Fisher Scientific

5.89 Uniogen

5.90 Veramarx

5.91 Veredus Laboratories

5.92 XCR Diagnostics

5.93 Zhejiang Orient Gene Biotech

6 Market Trends

6.1 Factors Driving Growth

6.1.1 New Genotypes Creating New Markets

6.1.2 Aging Population a Boon for All Diagnostics

6.1.3 Developing World Driving ID Dx Growth

6.1.4 Point of Care - Why Centralization is Losing Steam

6.1.5 Self Testing

6.1.6 The Need for Speed

6.2 Factors Limiting Growth

6.2.1 Lower Costs

6.2.2 Infectious Disease is Declining

6.2.3 Wellness Hurts

6.2.4 Economic Growth improves Living Standards

7 Molecular Dx - Infectious Disease Recent Developments

7.1 Recent Developments - Importance and How to Use This Section

7.1.1 Importance of These Developments

7.1.2 How to Use This Section

7.2 Cubit Dx Secures Funding for High-Sensitivity, Low-Cost Platform

7.3 Roche receives FDA clearance for STI at POC

7.4 Smartphone-Enabled Platform Transforms POC Testing

7.5 Credo Preps MDx System, Multiplex Respiratory Test for US Launch

7.6 A low-cost CRISPR-based paper strip test for flu

7.7 AMDI Receives Award to Develop 10 Minute POC Respiratory Panel

7.8 Roche to Acquire LumiraDx Point-of-Care Testing Tech

7.9 DiaSorin to Deliver Updated Instruments, New Assays in 2024/25

7.10 ReadyGo Diagnostics, Gemina Labs Expand MDx Pact

7.11 DiagMetrics Developing Breath Assays

7.12 Fortis Life Sciences Acquires IPOC

7.13 Domus Diagnostics Wins NIH RADx Tech Contract

7.14 Llusern Scientific to Launch POC MDx UTI Panel

7.15 Altratech Enters POC MDx Testing Space with Unique Tech

7.16 BioMerieux SpotFire MDx POC System Leverages Novel Approach

7.17 Katalyst Labs to Distribute ProtonDx Dragonfly Rapid IVD System

7.18 LEX Diagnostics Developing Ultra-Fast Low-Cost PCR

7.19 Sherlock Biosciences Adds to Infectious Disease Dx Toolkit

7.20 NanoDx Prepares for Point-of-Care Commercialization

7.21 Paragraf to Study New POC Test to Guide Antibiotic Selection

7.22 MicroGEM to Expand 30-Minute RT-PCR System

7.23 Startup Detect to Roll Out Next-Gen Molecular Instrument

7.24 Diagnostics for the Real World Third-Generation POC Platform

7.25 Salignostics Closes Funding Round

7.26 Cue Health Targets DTC Market in 2022

7.27 Grip Molecular Developing Home Respiratory Panel

7.28 Mainz Biomed Developing Home ColoAlert Assay

7.29 MFB Fertility Closes Series A Financing Round

7.30 Home Test Company Prenetics to go Public

7.31 Roche to Acquire TIB Molbiol to Expand Infectious Disease Portfolio

7.32 BforCure Preparing Multiple Panels for Point-of-Care qPCR Platform

7.33 Talis Biomedical Discusses Point-of-Care

7.34 Roche to Acquire GenMark Diagnostics for $1.8B

7.35 Pandemic Pushes Handheld qPCR Devices Closer to Commercialization

7.36 Hologic to Acquire Mobidiag

7.37 Lucira Health Focuses on User Friendly Approach to Home Testing

7.38 Infectious Disease Dx Firm Talis Biomedical Raises $254M in IPO

7.39 Fluidigm Plans 'Durable' Diagnostics, Clinical Business

7.40 Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M

7.41 Mammoth Biosciences Developing Pathogen Detection Tech

7.42 Illumina, IDbyDNA Developing Sequencing-Based Respiratory Tests

7.43 Scanogen Developing 90 Minute Infection Test

7.44 Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection

7.45 FDA Provides Self Testing SARS-CoV-2 EAU Guidance

7.46 Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic

7.47 Genetic Signatures Gets CE Mark for Coronavirus Molecular Test

7.48 Qiagen Respiratory Panel with Coronavirus Receives CE Mark

7.49 Lumos Diagnostics Closes $15M Series A Funding

For more information about this report visit https://www.researchandmarkets.com/r/cre83j

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250603843038/en/